ClinicalTrials.gg
Active, not recruitingNCT06313229Updated Aug 25, 2026

Simultaneous Implant Placement With Vertical and Horizontal Bone Augmentation

An interventional study of implant placement 6 months after ridge augmentation and implant placement Simultaneously with ridge augmentation in Alveolar Bone Loss and Dental Implant Failed, sponsored by Kafrelsheikh University. Active, not recruiting at 1 site in Egypt. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Kafrelsheikh University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Alveolar Bone Loss with a site in Egypt — 22 open to participants now, 27 under way, none of them phase 3. Alveolar Bone Loss · Egypt.

Enrollment
6th of 74
42 · median 20
Started
2024
with 15 others
No phase
68 of 75
19 open now
Primary completion
2027-04
later than 23 of 26 live
Registered
32nd of 75
by date
Lead sponsor
4 of 75
Kafrelsheikh University

Among the 75 studies in Alveolar Bone Loss with a site in Egypt, this one is the 6th largest by enrollment of the 74 interventional ones that give a count, is one of 16 that started in 2024, is one of 68 with no phase, reaches primary completion later than 23 of the 26 other live ones, and was the 32nd registered.

Alveolar Bone Loss

320 studies on the registry are indexed under Alveolar Bone Loss; 79 are open to participants now.

Browse Alveolar Bone Loss studies →

Open to participants now

22 of the 75 studies in Alveolar Bone Loss with a site in Egypt are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 47 Alveolar Bone Loss studies recruiting now, 19 (40%) set no upper age limit and 22 (47%) stop at 75 or younger; 4 take children under 18; 24 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Alveolar Bone Loss with a site in Egypt, or all of them as a file.
02

Study summary

The purpose of this study was to report the clinical and radiographical outcomes of using autogenous cortical bone plates combined with sticky allogenic bone graft for augmenting maxillary anterior atrophic combined horizontal and vertical ridge defects with simultaneous versus staged implant placement.

Read the detailed description

Sufficient alveolar ridge is a prerequisite for successful implant stability, atrophic ridges defects make the placement of regular implants challenging. A variety of materials and surgical techniques are available for bone augmentation procedures prior implant placement. The present study evaluated the effect of sticky allogenic bone graft for the horizontal and vertical ridge augmentation with simultaneous implant placement using autogenous cortical bone plates in maxillary anterior atrophic ridge defects.

Forty-two patients, with severe maxillary anterior horizontal and vertical atrophic ridge deficiencies were randomly assigned to two groups: staged approach group and simultaneous implant placement group. The two groups were grafted using bone plated buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft. Radiographic examination was performed immediately before bone grafting procedure and at 6, 12 months postoperatively, to evaluate the change of bone width and height.

03

Conditions studied

  • Alveolar Bone Loss
  • Dental Implant Failed

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good general health at the time of surgery
  • At least 3 months of healing after tooth extraction
  • Horizontally and vertical compromised alveolar ridges

Exclusion criteria

Exclusion Criteria:

  • Thick cortex in the labial/buccal with less cancellous bone inside;
  • Obvious undercut on the labial/buccal side
  • Uncontrolled periodontal conditions or other oral disorders;
  • history of radiotherapy in the head and neck region
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Staged implant placement approach

    the bone defect was grafted using bone plates buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft. 6 months later the implant was placed in the grafted site.

    Procedure: implant placement 6 months after ridge augmentation

  • Experimental
    Simultaneous implant placement approach

    the bone defect was grafted using bone plates buccally and palatally and the defect between plates was grafted by sticky allogenic bone graft combined with simultaneous implant placement.

    Procedure: implant placement Simultaneously with ridge augmentation

Interventions

  • Procedureimplant placement 6 months after ridge augmentation

    the deficient ridge was grafted first followed by implant placement after 6-monthes

  • Procedureimplant placement Simultaneously with ridge augmentation

    the deficient ridge was grafted and followed by implant placement simultaneously

06

What researchers measure

Primary outcomes

  1. Stability Quotient of Implants (SQI)

    The implant stability was recorded using Osstell TM. Following implant insertion, SQI readings were taken immediately, then again after six and twelve months.

    Time frame: 36-month.

  2. Horizontal bone dimensions (HBDs)

    The HBD alterations were assessed by measuring horizontal spacing between the external edges of labial and palatal bony plates at a level 2mm apical of the fixture platform.

    Time frame: 36-month.

  3. Peri-implant Bone Density (PBD)

    For consistent measurement of the PBD, 1-mm-diameter Region of interest (RI) was selected and traced 1.2 mm distant from the fixture on the cross-sectional slices followed by counting the threshold pixels inside the RI.

    Time frame: 36-month.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2027, 36 months after the start.

Of 169 non-industry interventional studies with no phase under Alveolar Bone Loss, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 30. This study's planned 36 months is above that.

Counting every sponsor, half of 169 studies reached it within 18 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2024
First posted
Mar 15, 2024
StartActual
Apr 15, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
May 18, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06313229
Responsible party
Walid Elamrousy (Assistant Professor of periodontology, Kafrelsheikh University) — Principal investigator
First posted
Mar 15, 2024
Start date
Apr 15, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
May 18, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

Walid AH Elamrousy, PhD
principal investigator · Faculty of Oral and Dental Medicine, Kafrelsheikh University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion